Who is the Patient? 4
- Section1.1
  
  Introduction
- Section1.2
  
  Precision/Personalization, Segmentation, and Incidence/Prevalence
- Section1.3
  
  Patient Journey
- Section1.4
  
  Expansion/Secondary Indications
Standard of Care & Competition 4
- Section2.1
  
  Introduction
- Section2.2
  
  Unmet Need, Safety, Efficacy, Compliance, Costs
- Section2.3
  
  Development Pipeline Analysis/Competitive Intelligence
- Section2.4
  
  Competition in Therapeutics (5 forces)
Business Model 4
- Section3.1
  
  Introduction
- Section3.2
  
  Product, Platform or Service
- Section3.3
  
  Mission, Vision, Strategy, Tactics, Operations
- Section3.4
  
  Who is the Customer?
Regulatory 4
- Section4.1
  
  Introduction
- Section4.2
  
  FDA Introduction
- Section4.3
  
  FDA Guidelines
- Section4.4
  
  Selecting FDA Consultants
Exit/End Goal 4
- Section5.1
  
  Introduction
- Section5.2
  
  Trade Sales
- Section5.3
  
  Sales
- Section5.4
  
  Partnerships

Introduction

Beginning with the end in mind is always good practice, but it doesn’t have to be slavish; building exit options, including the option not to exit (and to continue operating the business) is good business. Careful planning and execution are required to maximize value capture. Even with a successful therapeutic development in process (or over the finish line), the difference between a base hit and a home run here can be measured in orders of magnitude. We specifically exclude IPOs here as while they do produce liquidity, we believe they should primarily be viewed as a fundraising tactic, not an exit per se.

Resources

Prev Selecting FDA Consultants

Next Trade Sales

Modular Learning: Operations

Who is the Patient? 4

Standard of Care & Competition 4

Business Model 4

Regulatory 4

Exit/End Goal 4

Introduction

Resources

Modal title